You just read:

immatics to Receive Support From Pfizer for its Pivotal Phase III Study (IMPRINT) With IMA901, a Therapeutic Vaccine for Advanced Renal Cell Cancer Patients

News provided by

immatics

Apr 11, 2011, 03:00 ET